Public research disclosure · Oskar Fischer Prize entry
Research papers, references, and analysis by Richelle Gayle Cutler, Ph.D.
This site presents a body of work submitted as an entry for the Oskar Fischer Prize — an international challenge, funded through the University of Texas at San Antonio, to synthesize the literature and put forward a comprehensive explanation for the cause of Alzheimer’s disease. The central paper argues that occult herpesvirus infection is a non-genetic driver of the disease. The entry, its references, and an independent evaluation of the work are gathered here and made openly available as a public disclosure for scientific review.
Occult herpesvirus infection as a non-genetic driver of Alzheimer’s — set within a multifactorial model of the disease.
Dr. Cutler’s central proposal is that the common, lifelong herpesviruses most adults carry — usually silently are a major non-genetic driver of sporadic Alzheimer’s disease. Rather than one pathogen acting alone, several human herpesviruses (HSV-1 and -2, VZV, HCMV, HHV-6A/B, HHV-7, and EBV) converge beginning with alphaherpesvirus infection of neurons in the locus coeruleus. From there, infected locus coeruleus neuron axons projecting throughout the brain can selectly send infectious particles, non-infectious particles and viral exosomes to brain regions highly innervated by locus coeruleus processes that use kinesin for transporting vesicles. One regions that is particular susceptible is laminar I of the cerebral cortex. Laminar I is filled with interneurons that release GABA and modulate apical tuft dendrites of pyramidal neurons whose cell bodies reside in Layers II, III, and V. Latently infected neurons and other infected cell types can still secrete viral exosomes with viral proteins that cause neurodegeneration, e.g., VP22.
Thus, a distinctive feature of the model is that significant damage is carried by non-infectious secreted factors, so a small number of infected cells can injure many neighbours — “non-cell-autonomous” neurodegeneration. That helps explain a long-standing puzzle: why viral DNA is so hard to detect in end-stage Alzheimer’s brain tissue even if a virus set the disease in motion decades earlier.
The infectious idea is not new. Oskar Fischer and Alois Alzheimer both suspected, in 1907, that microbes might help form the plaques they described, and modern work has revived the theory — showing that herpesviruses can trigger the amyloid, tau, and neuroinflammatory hallmarks of the disease, and that amyloid-β itself can act as an antimicrobial peptide whose protective response turns harmful when infection becomes chronic.
These factors interact rather than simply add up:
This systems-level view fits Dr. Cutler’s own scientific training. Her doctoral research, in the neurogenetics laboratory of Dr. Robert W. Williams, mapped how genetic and environmental factors interact to shape a complex biological trait, and her postdoctoral work characterised non-cell-autonomous degeneration — the very mechanism the hypothesis places at the centre of Alzheimer’s pathology.
A plain-language summary for context; the full argument and its evidence are in the prize entry below.
A neurobiologist and registered patent agent whose work spans the bench and the patent office.
Richelle Gayle Cutler holds a Ph.D. in Neurobiology from the University of Tennessee Health Science Center and a B.S. in Biochemistry and Molecular Biology from the University of Maryland, Baltimore County. She trained in the Department of Anatomy and Neurobiology, in the neurogenetics laboratory of Dr. Robert W. Williams, where quantitative-trait-locus (QTL) mapping let her dissect how genetic and environmental factors together shape complex traits — quantifying their control over neuron number and brain size across mouse strains. The work grounded her in both complex-trait genetics and detailed neuroanatomy — mapping and counting neuronal populations across the brain and retina — and she taught medical students both gross anatomy and neuroanatomy. That gene-by-environment, whole-system training is the same thinking that runs through her multifactorial view of Alzheimer’s disease.
Her engagement with the disease is long-standing. Among her earliest peer-reviewed work is a study of altered muscarinic (cholinergic) signal transduction in aging and Alzheimer’s brain (Brain Research, 1994). She went on to study neurodegeneration directly: as a post-doctoral fellow at the Johns Hopkins Wilmer Eye Institute she led the development and characterization of a tetracycline-inducible transgenic mouse model of retinitis pigmentosa, examining the mechanism of non-cell-autonomous cone-cell degeneration — the same non-cell-autonomous principle that anchors the herpesvirus theory presented here.
At the Fred Hutchinson Cancer Research Center she developed a competitive binding assay to optimize the targeting of pH-responsive micelles carrying siRNA to lymphoma cells, and ran siRNA-mediated gene-knockdown experiments using RT-qPCR and high-throughput fluorometric enzyme assays. That combination of molecular neuroscience and therapeutic delivery underlies the technical range she later brought to patent practice.
Registered before the U.S. Patent and Trademark Office in 2015, she has more than six years drafting and prosecuting U.S. and international patent applications across the life sciences — virology, immunology, recombinant fusion proteins, genomics, antibodies, CRISPR gene editing, RNA interference, recombinant bacteria, and small-molecule drugs — including work supporting academic inventors and university technology transfer. She is the sole inventor on U.S. Patent No. 12,428,643, directed to RNA interference in therapeutic compositions and methods of treatment. A continuation of that patent is pending, published as U.S. 2026/0098267 A1, and a further application, published as PCT WO 2025/097185 A1, is pending in the U.S. national phase.
Honigman LLP · Ann Arbor, MI
Drafted and prosecuted U.S. and international applications, managed multiple client portfolios, and developed global prosecution strategy with attorneys. Conducted patentability and clearance searches across public and proprietary databases and generated complex sequence listings with WIPO Sequence Suite.
Independent practice · Seeking Alpha contributor
Drafted and filed applications focused on RNA interference in therapeutic compositions; prepared sequence listings and information disclosure statements. Evaluated biotech companies on clinical likelihood, IP position, competitive landscape, leadership, and financials.
Strom Patent Law Firm · Woodinville, WA
Prepared and filed the full range of USPTO documents — amendments, petitions, terminal disclaimers, declarations, assignments, and IDSs. Coordinated with Microsoft inventors and IP managers on formal documents and tracked deadlines via the Memotech docketing system.
University of Washington, CoMotion · Seattle, WA
Supported university technology transfer: performed patentability analyses including structure similarity searches in SciFinder, and prepared a response defending an applicant’s CRISPR invention against a third-party prior-art submission.
Fred Hutchinson Cancer Research Center · Seattle, WA
Built a competitive binding assay for antibody-targeted, siRNA-loaded pH-responsive micelles and ran gene-knockdown experiments by RT-qPCR and fluorometric enzyme assay.
Johns Hopkins Hospital, Wilmer Eye Institute · Baltimore, MD
Lead investigator on a tetracycline-inducible transgenic mouse model of retinitis pigmentosa, studying the mechanism of non-cell-autonomous cone-cell degeneration.
Doctoral-era work was published under the name R. C. Strom. See also her Google Scholar profile and doctoral CV at the Williams Laboratory (nervenet.org).
The CV above is the full text; the PDF is the same document, formatted for download and easy to attach to an email.
Herpesviruses as a non-genetic driver of Alzheimer’s disease — the full paper, transcribed for open reading with all figures.
Occult herpesvirus infections could be the non-genetic driver of sporadic Alzheimer’s disease. Neurotropic alphaherpesviruses can infect adrenergic neurons of the locus coeruleus, where secreted viral factors — such as herpesvirus glycoprotein B — disrupt endosomal trafficking, displace amyloid precursor protein (APP) from the cell surface, and drive amyloidogenesis and tau hyperphosphorylation.
Loss of APP destabilizes inhibitory α2-adrenergic autofeedback, producing persistent norepinephrine release and a cascade that links immunosuppression, insulin deficiency, vascular inflammation, and hypoxia. Because the damage is carried by secreted factors, a small number of infected cells can produce the diffuse degeneration seen in Alzheimer’s — explaining why viral DNA is so hard to detect. The paper argues that multiple herpesvirus types act together in disease pathogenesis.
Keywords — herpesvirus · hypoxia · amyloid-precursor-protein · immunosuppression · opportunistic infections
The literature the entry is built on — 245 cited sources, each linked for lookup.
The argument draws on 245 peer-reviewed sources spanning virology, neuropathology, immunology, vascular biology, and genetics — from foundational Alzheimer’s staging work to herpesvirus molecular biology and the epidemiology linking infection to dementia risk.
The full list is browsable on its own page, in the citation order used throughout the paper, with a live filter for finding an author, journal, or year. Every entry carries a one-click PubMed and Google Scholar lookup so any citation can be traced to its source.
An independent, AI-generated critical evaluation of the entry — scored against the Oskar Fischer Prize criteria.
A doctoral-thesis-style review assesses the herpesvirus theory against the Convergent Autophagic Collapse model of Alzheimer’s — a six-stage account of lysosomal failure. It maps the entry’s viral mechanisms (pp150–Rab6 displacement, UL56/APP mimicry, gB-seeded amyloidosis) onto that pathway and proposes a unified “viral-secretory-lytic” synthesis, before scoring the work against the prize criteria.
This document is AI-generated and provided for discussion — not peer review, and not the view of the author, the prize, or UTSA.